Ceryvyn Therapeutics Ltd
OPT
Κατάταξη σε μετοχές
#31859
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Τιμή μετοχής
$0.00846342
Τελευταίος συγχρονισμός: 2026-07-27
Κεφαλαιοποίηση
$11.27M
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
-99.75%
Χώρα
AU
Εμπόριο Ceryvyn Therapeutics Ltd (OPT)
Κατηγορία
Healthcare
Κέρδη για την Ceryvyn Therapeutics Ltd (OPT)
Κέρδη τον Jun 2025 TTM: $-169.06M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Ceryvyn Therapeutics Ltd, τα τρέχοντα κέρδη της εταιρείας είναι $-169.06M. Το 2024, η εταιρεία παρουσίασε κέρδη $-229.65M, μείωση σε σύγκριση με των κερδών του 2023 που ήταν $-220.69M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Ceryvyn Therapeutics Ltd από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-169.06M | -1.22% |
| 2025 | $-171.16M | -25.47% |
| 2024 | $-229.65M | 4.06% |
| 2023 | $-220.69M | 61.47% |
| 2022 | $-136.68M | 102.76% |
| 2021 | $-67.41M | 300.56% |
| 2020 | $-16.83M | -32.59% |
| 2019 | $-24.96M | 16.56% |
| 2018 | $-21.42M | 197.14% |
| 2017 | $-7.21M | 19.44% |
| 2016 | $-6.03M | 25.84% |
| 2015 | $-4.80M | -21.15% |
| 2014 | $-6.08M | 11.14% |
| 2013 | $-5.47M | -28.41% |
| 2012 | $-7.64M | -39.60% |
| 2011 | $-12.66M | 157.11% |
| 2010 | $-4.92M | -23.67% |
| 2009 | $-6.45M | 529.14% |
| 2008 | $-1.03M | -111.84% |
| 2007 | $8.66M | -354.34% |
| 2006 | $-3.40M | -126.95% |
| 2005 | $12.63M | 348.18% |
| 2004 | $2.82M | -271.74% |
| 2003 | $-1.64M | -9.95% |
| 2002 | $-1.82M | 332.65% |
| 2001 | $-421.07K | -196.28% |
| 2000 | $437.36K | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | -3,220.05% |
US
|
|
| $-3.09B | 1,725.93% |
US
|
|
| $-4.02B | 2,275.54% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,253.79% |
NL
|
